Pharmaceutical Business review

Autodesk to develop new software for Organovo 3D bioprinter

Three-dimensional human tissues or models are designed for use in the medical research, drug discovery and development.

Organovo chairman and chief executive officer Keith Murphy said, "This relationship will lead to advances in bioprinting, including both greater flexibility and throughput internally, and the potential long-term ability for customers to design their own 3D tissues for production by Organovo."

Autodesk senior vice president and chief technology officer Jeff Kowalski said, "I think working with Organovo to explore and evolve this emerging field will yield some fascinating and radical advances in medical research."

In the future, the bioprinting technology can also be used in surgical therapies and transplantation, claims the company.